3/13
08:14 am
urgn
UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence [Yahoo! Finance]
Low
Report
UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence [Yahoo! Finance]
3/13
08:00 am
urgn
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
Low
Report
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
3/6
04:10 pm
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5
03:02 am
urgn
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push [Yahoo! Finance]
Low
Report
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push [Yahoo! Finance]
3/5
01:56 am
urgn
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers [Seeking Alpha]
Low
Report
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers [Seeking Alpha]
3/3
07:23 am
urgn
UroGen Pharma Ltd. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
UroGen Pharma Ltd. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/2
04:22 pm
urgn
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
Low
Report
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
3/2
01:05 pm
urgn
Urogen Pharma (URGN) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Medium
Report
Urogen Pharma (URGN) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
3/2
01:01 pm
urgn
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/2
12:40 pm
urgn
Urogen Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Urogen Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
3/2
11:56 am
urgn
UroGen (URGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
UroGen (URGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/2
10:56 am
urgn
Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.
Medium
Report
Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.
3/2
08:23 am
urgn
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/2
08:11 am
urgn
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors [Yahoo! Finance]
High
Report
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors [Yahoo! Finance]
3/2
08:00 am
urgn
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
High
Report
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
3/2
07:55 am
urgn
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
High
Report
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
2/27
08:50 am
urgn
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC [Yahoo! Finance]
Medium
Report
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC [Yahoo! Finance]
2/27
08:30 am
urgn
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
Medium
Report
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
2/24
04:25 pm
urgn
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
04:05 pm
urgn
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
Low
Report
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
2/23
08:00 am
urgn
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
Low
Report
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
2/15
08:11 pm
urgn
UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target [Yahoo! Finance]
Low
Report
UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target [Yahoo! Finance]
2/4
08:00 am
urgn
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
Medium
Report
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
1/23
08:04 am
urgn
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.
Neutral
Report
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.
1/6
08:46 am
urgn
UroGen Pharma says permanent J Code for ZUSDURI now in effect [Yahoo! Finance]
Low
Report
UroGen Pharma says permanent J Code for ZUSDURI now in effect [Yahoo! Finance]